HealthDay - THURSDAY, April 9 (HealthDay News) -- Seniors who were overweight or obese earlier in life are at increased risk for physical disabilities, even if they've shed the excess weight they had when they were younger, says a new U.S. study.
AP - A liquid morphine painkiller given by family caregivers to dying patients can remain on the market, federal regulators have decided after hearing protests over their decision to remove it. The Food and Drug Administration had announced last week that it was ordering manufacturers to stop making 14 medications including the liquid morphine. All were developed so long ago they had never received FDA approval.
AP - A liquid morphine painkiller given by family caregivers to dying patients can remain on the market, federal regulators have decided after hearing protests about their decision to remove it.
AP - Shriners Hospitals for Children, which has provided free care since before the Great Depression, is considering closing a quarter of its facilities as donations stagnate, costs increase and the charity's endowment shrivels.
HealthDay - THURSDAY, April 9 (HealthDay News) -- Seniors who were overweight or obese earlier in life are at increased risk for physical disabilities, even if they've shed the excess weight they had when they were younger, says a new U.S. study.
AP - An extensive investigation has failed to determine how E. coli bacteria was introduced into a northeastern Oklahoma restaurant linked to hundreds of illnesses and one death, the state health board said in a report released Thursday.
AP - Americans didn't suffer more food poisoning last year despite high-profile outbreaks involving peppers, peanut butter and other foods, according to a government report released Thursday. Rates of food-borne illnesses have been holding steady for five years. They had been declining from the mid-1990s until the beginning of this decade, due mainly to improvements in the meat and poultry industry, some experts say.
Reuters - Italian biotech Bioxell SpA said its Elocalcitol drug to treat overactive bladder (OAB) failed to reach its main target in a mid-stage clinical trial, and that it would cut costs, sending its stock to an all-time low.
This email was sent to createrofheaven.healthnewsupdates@blogger.com. Create Your Account Don't want to receive this feed any longer? Unsubscribe here.
0 comments:
Post a Comment